Table 2

Comorbidities of patients undergoing bilateral or unilateral total knee arthroplasty

ComorbidityGroup, no. (%)*p valueOR (95% CI)
UTKA, n = 966BTKA, n = 373
Cardiovascular
 Hypertension553 (57.2)222 (59.5)0.460.9 (0.7–1.2)
 Arrhythmia107 (11.1)29 (7.8)0.091.5 (1.0–2.3)
 Coronary artery disease108 (11.2)38 (10.2)0.631.1 (0.8–1.6)
 Myocardial infarction60 (6.2)25 (6.7)0.710.9 (0.6–1.5)
 Chronic heart failure14 (1.4)4 (1.1)0.791.4 (0.4–4.2)
Thromboembolic
 Deep vein thrombosis23 (2.4)11 (2.9)0.560.8 (0.4–1.7)
 Pulmonary embolism8 (0.8)3 (0.8)> 0.991.0 (0.3–3.9)
Neurologic
 Transient ischemic attack33 (3.4)4 (1.1)0.0153.3 (1.1–9.3)
 Stroke25 (2.6)7 (1.9)0.551.4 (0.6–3.2)
 Dementia8 (0.8)1 (0.3)0.463.1 (0.4–24.9)
Respiratory
 Asthma97 (10.0)34 (9.1)0.681.1 (0.7–1.7)
 COPD40 (4.1)10 (2.7)0.261.6 (0.8–3.2)
 Renal failure32 (3.3)6 (1.6)0.102.1 (0.9–5.1)
Diabetes172 (17.8)72 (19.3)0.530.9 (0.7–1.2)
Previous knee surgery196 (20.3)21 (5.6)< 0.0014.3 (2.7–6.8)
Preop Hb status
 Preop Hb, mean ± SD, g/L134.7 ± 13.5133.1 ± 13.70.211.01 (1.0–1.02)
 Preop anemia, mean ± SD, g/L320.0 ± 33.1118.0 ± 31.60.651.1 (0.8–1.4)
  • BTKA = bilateral total knee arthroplasty; CI = confidence interval; COPD = chronic obstructive pulmonary disease; Hb = hemoglobin; OR = odds ratio; SD = standard deviation; UTKA= unilateral total knee arthroplasty.

  • * Unless otherwise indicated.

  • Hb < 130 g/L.